President Trump announced that the U.S. government will provide GLP-1 drugs (weight-loss and diabetes medications) to Medicare patients. The statement signals potential government coverage expansion for these expensive medications.

• •Trump said the U.S. will provide GLP-1 drugs to Medicare patients
• •Announcement signals potential federal coverage expansion for GLP-1s

The FDA is proposing to remove weight-loss drugs made by Novo Nordisk and Eli Lilly from a list of medicines that pharmacies can copy and make in bulk. This would be good for the companies because it would force more patients to buy their brand-name versions instead of cheaper pharmacy-made copies.

• •FDA proposes excluding Novo and Lilly weight-loss drugs from bulk compounding list
• •Move would restrict pharmacies from making bulk copies of the drugs
• •Patients would be pushed toward brand-name versions

Health Canada approved the first generic version of semaglutide (Ozempic), Novo Nordisk's popular diabetes and weight-loss drug. This means Canadian patients may soon have access to a cheaper alternative to the brand-name version.

• •Health Canada approved the first generic version of Ozempic (semaglutide).
• •Approval covers Novo Nordisk's diabetes and weight-loss drug.
• •Canadian patients may gain access to a cheaper alternative to the brand.

A drug made by Boehringer Ingelheim and Zealand Pharma helped people lose 16.6% of their body weight in a late-stage trial (a big test before the FDA decides whether to approve a medicine). This is positive news for the companies' weight-loss drug program.

• •Boehringer-Zealand drug delivered 16.6% weight loss in late-stage trial
• •Trial is Phase 3 (pre-FDA decision stage)

Boehringer Ingelheim's survodutide, a dual-action drug that targets two hormones (glucagon and GLP-1) to help with weight loss, showed people lost an average of 16.6% of their body weight in a late-stage trial. The drug also improved other measures of metabolic health in people with obesity or excess weight.

• •Survodutide delivered 16.6% weight loss in Phase 3 obesity trial
• •Drug is a glucagon/GLP-1 dual agonist from Boehringer Ingelheim, partnered with Zealand
• •Trial showed metabolic improvements in people with obesity or overweight

Eli Lilly's retatrutide, a next-generation weight-loss drug, has passed its first major late-stage trial (Phase 3 trial), which tests whether a drug actually works in patients. This is an important step toward getting the drug approved by regulators.

• •Retatrutide passed its first Phase 3 trial
• •Drug is positioned as Lilly's next-generation obesity therapy
• •Result advances retatrutide toward regulatory submission

Novo Nordisk is lowering the advertised U.S. prices for Ozempic (a diabetes drug) and Wegovy (a weight-loss drug) by as much as 50%. This is the company's move to make these expensive medications more affordable for patients and insurers.

• •Novo Nordisk to cut US list prices for Ozempic and Wegovy by up to 50%
• •Move targets affordability for patients and insurers

Boehringer Ingelheim announced that survodutide, a dual-action drug that works like both glucagon and GLP-1 (weight-loss hormones), helped people lose 16.6% of their body weight in a Phase III trial (a large late-stage test). The drug also improved other health markers related to metabolism in people with obesity or excess weight.

• •Survodutide hit 16.6% weight loss in Phase III obesity trial
• •Drug is a glucagon/GLP-1 dual agonist from Boehringer Ingelheim
• •Trial showed metabolic improvements in obesity/overweight patients

Apotex, a Canadian drugmaker, got approval from Health Canada to sell a generic copy of Ozempic (semaglutide), a popular weight-loss and diabetes medicine. This is the first generic version approved by Canada's health regulator.

• •Apotex received Health Canada approval for a generic equivalent of Ozempic (semaglutide)
• •First Canadian-based pharma company to win generic Ozempic approval in Canada

Canada approved a generic version of semaglutide (the active ingredient in Ozempic) made by Dr. Reddy's Laboratories. This generic copy is cheaper and could give more people access to the weight-loss and diabetes drug.

• •Canada approved Dr. Reddy's generic version of semaglutide
• •Semaglutide is the active ingredient in Novo Nordisk's Ozempic
• •Generic is cheaper and aims to broaden access for diabetes and weight loss

Dr. Reddy's Laboratories received approval from Health Canada to sell a generic version of semaglutide injection in Canada. This is the first generic copy of the popular weight-loss and diabetes drug to be approved there.

• •Dr. Reddy's received Health Canada approval for generic semaglutide injection
• •First generic semaglutide approved in Canada
• •Approval covers weight-loss and diabetes indications

Canada's health authority approved the first generic copy of semaglutide (Ozempic), the popular weight-loss and diabetes drug. This approval means cheaper versions of the medicine may become available as more companies compete to make GLP-1 drugs.

• •Canada approved the first generic version of semaglutide (Ozempic)
• •Approval opens the door to cheaper GLP-1 alternatives in Canada
• •Decision arrives amid rising competition in the GLP-1 class

• •Boehringer's dual-acting obesity shot met its endpoint in a Phase 3 trial

• •Boehringer's dual agonist hit 16.6% weight loss in phase 3
• •Phase 3 readout leaves key questions unanswered

Canada approved a generic version of semaglutide, the active ingredient in Ozempic. This means Canadian patients may have access to a cheaper alternative to the brand-name weight-loss and diabetes drug.

• •Canada approved a generic version of semaglutide, the active ingredient in Ozempic.
• •Generic entry positions Canadian patients for a cheaper alternative to brand-name Ozempic.

Canada's health regulator approved a second generic copy of semaglutide (Ozempic), the popular diabetes and weight-loss drug made by Novo Nordisk. More generic options could help lower costs for patients in Canada.

• •Canada's health regulator approved a second generic version of semaglutide (Ozempic)
• •Ozempic is made by Novo Nordisk
• •More generic options could help lower costs for patients in Canada

Canada's health authority approved a second generic version of semaglutide (Ozempic), the popular weight-loss and diabetes drug. More generic copies available could lower prices and help more people afford the medicine.

• •Canada approved a second generic version of semaglutide (Ozempic)
• •Additional generics expected to lower prices and broaden access

Health Canada approved a second generic version of semaglutide (the active ingredient in Ozempic), made by a Canadian company. This gives patients another cheaper alternative to the brand-name weight-loss and diabetes drug.

• •Health Canada approved a second generic version of semaglutide
• •The generic is manufactured by a Canadian company
• •Ozempic is Novo Nordisk's branded semaglutide for diabetes and weight loss

Canada approved a second generic version of Ozempic (a semaglutide injection used for diabetes and weight loss). This expands access to cheaper copies of the drug beyond Novo Nordisk's brand-name version.

• •Canada approved a second generic version of Ozempic (semaglutide injection)
• •Generic is indicated for diabetes and weight loss
• •Approval adds a second copycat competing with Novo Nordisk's brand

Canada has approved a second generic copy of semaglutide (the drug in Ozempic). This means more affordable versions of the popular weight-loss and diabetes medicine are becoming available to Canadian patients.

• •Canada approved a second generic version of semaglutide
• •Semaglutide is the active ingredient in Novo Nordisk's Ozempic

Novo Nordisk's oral form of Ozempic (a GLP-1 peptide drug for type 2 diabetes) has FDA approval and will soon be available in the United States. This is the first FDA-approved pill version of a GLP-1 peptide medication for adults with type 2 diabetes.

• •FDA approved Novo Nordisk's oral Ozempic for adults with type 2 diabetes
• •Positioned as the only FDA-approved oral peptide GLP-1 for T2D
• •US launch imminent per Novo Nordisk

Novo Nordisk's oral version of Ozempic (a GLP-1 peptide drug used for type 2 diabetes) will become available in the United States soon. This is the only FDA-approved pill form of this type of medication for adults with diabetes.

• •Novo Nordisk's oral Ozempic to become available in the US soon
• •Only FDA-approved oral peptide GLP-1 for adults with type 2 diabetes

The FDA is taking action against bulk production of obesity drug ingredients, which helped stock prices rise for Eli Lilly and Novo Nordisk. This move could benefit the companies by reducing competition from cheaper, bulk-made versions of weight-loss medicines.

• •FDA moving against bulk production of obesity drug ingredients
• •Eli Lilly and Novo Nordisk shares rose on the news

Boehringer Ingelheim's survodutide, a GLP-1 dual agonist (a type of weight-loss and diabetes drug), showed positive results in a large Phase 3 trial (a major test required before FDA approval). The company is advancing the drug toward regulatory approval based on these successful trial results.

• •Boehringer Ingelheim's survodutide hit positive results in a Phase 3 trial
• •Survodutide is a GLP-1/glucagon dual agonist for weight loss and diabetes
• •Company advancing the drug toward regulatory approval

Dr. Reddy's has received approval to sell a generic version of semaglutide (Ozempic), a popular weight-loss and diabetes drug. The article indicates pricing information for this generic option will be available, potentially offering a lower-cost alternative to the brand-name version.

• •Dr Reddy's received approval to sell a generic version of semaglutide (Ozempic)
• •Generic launch positioned as lower-cost alternative to brand-name Ozempic

Survodutide, a drug that works on two different body signals to reduce weight, showed strong results in a Phase 3 trial (a large test needed before the FDA considers approval). The trial tested whether survodutide could help people with obesity lose weight.

• •Survodutide met endpoints in a Phase 3 obesity trial
• •Drug is a dual agonist mechanism
• •Trial tested weight loss in patients with obesity

Dr. Reddy's Laboratories received approval from Health Canada (the Canadian health regulator) to sell a generic version of semaglutide injection in 2 mg and 4 mg pen formats. This approval means Canadians will have access to a cheaper copy of this popular weight-loss and diabetes drug.

• •Health Canada approved Dr. Reddy's generic semaglutide injection
• •Approval covers 2 mg and 4 mg pen formats